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Abstract
Introduction: The potential association between hypo- and hyperthyroid disorders and breast cancer has been 
investigated in a large number of studies during the last decades without conclusive results. This prospective cohort 
study investigated prediagnostic levels of thyrotropin (TSH) and triiodothyronine (T3) in relation to breast cancer 
incidence in pre- and postmenopausal women.
Methods: In the Malmö Preventive Project, 2,696 women had T3 and/or TSH levels measured at baseline. During a 
mean follow-up of 19.3 years, 173 incident breast cancer cases were retrieved using record linkage with The Swedish 
Cancer Registry. Quartile cut-points for T3 and TSH were based on the distribution among all women in the study 
cohort. A Cox's proportional hazards analysis was used to estimate relative risks (RR), with a confidence interval (CI) of 
95%. Trends over quartiles of T3 and TSH were calculated considering a P-value < 0.05 as statistically significant. All 
analyses were repeated for pre- and peri/postmenopausal women separately.
Results: Overall there was a statistically significant association between T3 and breast cancer risk, the adjusted RR in 
the fourth quartile, as compared to the first, was 1.87 (1.12 to 3.14). In postmenopausal women the RRs for the second, 
third and fourth quartiles, as compared to the first, were 3.26 (0.96 to 11.1), 5.53 (1.65 to 18.6) and 6.87 (2.09 to 22.6), (P-
trend: < 0.001). There were no such associations in pre-menopausal women, and no statistically significant interaction 
between T3 and menopausal status. Also, no statistically significant association was seen between serum TSH and 
breast cancer.
Conclusions: This is the first prospective study on T3 levels in relation to breast cancer risk. T3 levels in 
postmenopausal women were positively associated with the risk of breast cancer in a dose-response manner.
Introduction
Thyroid disorders and breast cancer both have a post-
menopausal peak incidence, and a potential association
between hypo- and hyperthyroid disorders and breast
cancer has been investigated in a large number of studies
during the last decades [1-19]. However, the results have
not been conclusive.
Experimental studies have shown that thyroid hor-
mones can have estrogen-like effects in breast cancer, and
that thyroid hormone receptors influence both normal
breast cell differentiation and breast cancer cell prolifera-
tion [2,3]. Several clinical and epidemiological cross-sec-
tional studies have been performed comparing levels of
triiodothyronine (T3), thyroxin (T4) and thyrotropin
(TSH) in breast cancer patients versus healthy controls.
T h e  r e s u l t s  h a v e  b e e n  c o n t r a d i c t o ry ,  s o m e  i n  f a v o r  o f
higher levels in cases [4-7] other in controls [8] and yet
some report no differences [9-15].
It is, however, difficult to conclude from cross-sectional
studies whether differences in thyroid hormone levels are
associated with different risks of breast cancer, or if
breast cancer itself alters thyroid hormone levels. To date,
there is only one prospective cohort study on this issue,
involving 61 breast cancer cases, where pre-diagnostic
levels of TSH and T4 were related to subsequent risk of
breast cancer [16]. The present study is a population
based, prospective cohort study including 2,696 pre and
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peri/postmenopausal women in whom TSH and T3 levels
were measured at baseline. During a follow-up of a total
of 51,989 person-years, 173 women were diagnosed with
incident breast cancer.
The aim of the present study was to investigate prediag-
nostic serum levels of TSH and T3 in relation to breast
cancer incidence in pre- and peri/postmenopausal
women, respectively.
Materials and methods
The Malmö Preventive Project
Originally, 10,902 women participated in the Malmö Pre-
ventive Project. The project was established in 1974 when
residents in Malmö, a city in southern Sweden, were
invited to participate in a health survey. Entire birth
cohorts, men and women, were examined until 1992
when the department closed. Approximately 70% of
invited subjects participated.
All participants answered a questionnaire concerning
socio-demographic information, lifestyle habits, and
medical history. Questions on reproductive factors, use
of oral contraceptives (OC), and hormonal replacement
therapy (HRT), were only included in women screened
from April 1983 and onwards (8,051 subjects). There was
no information on type of HRT. Body mass index (BMI)
(kg/m2) was assessed by a trained nurse on baseline
examination. A subject was considered to have a previous
history of goiter if the question 'have you been treated for
goiter' was answered with 'yes'. There was no available
information on type of treatment.
The participants were initially part of a preventive
health care project. All former participants were
informed about the present study by newspaper as
required by the local ethical committee. All participants
were offered to be excluded from the present study.
Triiodothyronine (T3) and thyrtropin (TSH) analysis
Blood samples were taken after an overnight fast with the
patient in the supine position. The serum samples were
analyzed for T3 and TSH in women born in 1928 and
1941 and examined in 1983 and 1984. In women born in
1935 (examined from 1990 to 1992), TSH levels were
measured in all, but T3 was only measured in a sub-set of
all women. In women born in 1935, T3 was analyzed in
those with pathological TSH values, a history of thyroid
disease, or those with an enlarged thyroid gland at exami-
nation. In addition to this, the attending physician could
also decide to analyze T3. The basis for the decision to
analyze T3 in an individual subject was not recorded sys-
tematically.
T3 was measured by a double anti-body radioimmuno-
assay (reference interval 0.9 to 3.2 mmol/l) [20]. Only six
women had a value above the upper reference limit. TSH
was also measured by a double anti-body radioimmuno-
assay [20] in 1983 and 1984 (period I, reference interval
<8 mIU/l), whereas a immunoradiometric analysis
(IRMA) was used in 1990 to 1992 (period II, reference
interval 0.4 to 4.0 mIU/l). Data on coefficients of varia-
tion from the laboratory analysis were unfortunately not
available.
Study cohort
Among 10,902 women, reproductive data including
menopausal status had been assessed in 8,051 subjets.
Serum TSH had been measured in 2,944 of these (women
born in 1928, 1941 and 1935, respectively). Those with
prevalent breast cancer (n = 46), goiter (n = 196) or both
of these conditions (n = 6) were identified and excluded
from the study.
Finally, 2,696 women constituted our study population.
Information on T3 was not available for all women born
in 1935, and T3 had been assessed in 2,185 out of all
2,696 women. The present study was approved by the
ethical committee at Lund University, Sweden: Dnr 652/
2005 and Dnr 501/2006.
Follow-up
Breast cancer cases, invasive and in situ, were retrieved
up until 31 December 2006 by record linkage with The
Swedish Cancer Registry (until 31 December 2005) and,
due to a one-year delay in registration, also from its
regional branch, The Southern Swedish Regional Cancer
Registry (cases diagnosed in 2006). Among 2,696 women,
there were 173 incident breast cancer cases. Information
on vital status was retrieved from the Swedish Cause-of-
Death Registry.
Mean follow-up was 19.3 (5.08) years and total follow-
up was 51,989 person-years.
Statistical methods
Quartile cut-points for T3 and TSH were based on the
distribution among all women in the study cohort. Due to
the change of method of analysis of TSH, separate cut-
points were used for samples analyzed before and after
this change.
Each woman was followed until the end of follow-up,
31 December 2006, or until she got breast cancer or died.
The incidence of breast cancer per 100,000 person-years
was calculated in different quartiles of T3 and TSH. A
Cox's proportional hazards analysis was used to estimate
corresponding relative risks (RR) with a confidence inter-
val (CI) of 95%. Possible confounding factors, that is,
established and potential risk factors for breast cancer,
were introduced as covariates in a subsequent analysis.
Age was entered as a continuous variable and all other
factors were entered as categorical variables classified as
in Tables 1 and 2 (menopausal status, use of HRT, num-
ber of children, use of oral contraception, age at menar-
che, smoking status, alcohol consumption, BMI, height,Tosovic et al. Breast Cancer Research 2010, 12:R33
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Table 1: Distribution of potential risk factors for breast cancer according to serum T3 level
Factor T3 quartile
12 3 4 A l l
N = 494 N = 704 N = 456 N = 531 N = 2,185
Column percent
(T3 levels in italics)
T3 (mIU/l) <1.50 1.60 to 1.80 1.90 to 2.00 2.1 to -4.30
Age
<50 62.1 46.6 26.1 21.5 39.7
>50 37.9 53.4 73.9 78.5 60.3
Premenstrual 60.3 44.2 28.7 23.2 39.5
Peri/postmenopausal 39.7 55.8 71.3 76.8 60.5
HRT in peri/postmenopausal 13.3 14.2 15.4 17.6 15.4
missing - - 0.3 - 0.1
Nulliparity 18.2 17.0 13.2 19.6 17.1
missing - - 0.4 0.8 0.3
OC-use 4.7 6.0 9.0 11.5 7.6
missing - - 0.7 0.9 0.4
Menarche <12 years 15.2 13.4 9.6 11.9 12.6
missing - 0.4 1.3 1.3 0.7
Smoking
never 43.5 47.7 47.6 47.1 46.6
current 35.8 33.2 34.0 33.1 34.0
ex 20.6 19.0 18.0 18.8 19.1
missing - - 0.4 0.9 0.3
Alcohol consumption
nothing 14.2 14.1 13.2 19.0 15.1
less than every week 55.3 60.7 62.5 60.1 59.7
every week 30.6 25.1 23.9 19.4 24.7
missing - 0.1 0.4 1.5 0.5
BMI
<20 14.8 10.1 7.9 7.5 10.1
≥20 <25 62.3 56.1 53.9 46.5 54.7
≥25 <30 17.0 26.1 27.9 30.5 25.5
≥30 5.9 7.7 10.3 15.4 9.7
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http://breast-cancer-research.com/content/12/3/R33
Page 4 of 12
educational level and marital status). Trends over
quartiles of T3 and TSH were calculated by introducing
the quartile number as a continuous variable in the analy-
sis. A P-value < 0.05 was considered as statistically signif-
icant.
Breast cancer may be associated with different risk fac-
tors in peri/postmenopausal versus premenopausal
women. Furthermore, both thyroid conditions and breast
cancer have been associated with BMI [21,22]. Following
this, all analyses were repeated for pre- and peri/post-
menopausal women separately, and stratified for BMI
(BMI <25 vs. BMI ≥25). The potential interaction
between T3/TSH and menopausal status was tested by
adding an interaction term in the Cox analysis. A P-value
<0.05 was considered indicative of a statistically signifi-
cant interaction.
It has been reported that the relation between TSH and
T3/T4 may be disturbed in breast cancer patients, hence
the presence of undiagnosed breast cancer may affect
thyroid hormone levels [16,23,24]. Consequently, cases
diagnosed within three years after baseline examination
and subjects with less than three years follow-up were
excluded in an additional analysis. As it is possible that
certain combinations of T3/T4 and TSH can be related to
an increased risk of breast cancer, different combinations
of low (below median) and high (above median) TSH and
T 3 we r e  e xam ined in r e la t io n t o ris k of  br eas t  ca nc e r .
M o r e o v e r ,  t h e  r i s k  o f  b r e a s t  c a n c e r  i n  r e l a t i o n  t o  T 3
quartiles was analyzed in different strata of TSH (below
and above the median). Interaction between T3 and TSH
was investigated by entering an interaction term in the
Cox analysis. T3 was entered as quartiles, and TSH as a
dichotomies variable (below/above median).
Since T3 was not measured in the whole group born in
1935, the analysis of T3 was repeated including only
women born in 1928 and 1941.
Due to the potential effect of estrogens on thyroxin
binding globulin (TBG) concentration, and hence the lev-
els of T3, an additional analysis was executed excluding
women treated with HRT or OC.
Results
Advanced age, peri/postmenopausal status, use of OC,
HRT and high BMI, were more common in high T3
quartiles (Table 1). With regard to TSH, the highest per-
centage of peri/postmenopausal women, were in the low-
est and highest TSH quartiles, respectively (Table 2).
Overall, the risk of breast cancer was statistically signif-
icantly higher in the fourth T3 quartile as compared to
the first quartile (Table 3). This association was even
stronger for postmenopausal women, also showing a
marked dose-response pattern (P-value for trend <
0.001). No such associations were seen in premenopausal
women. There were no statistically significant interac-
tions between menopausal status and T3 (P: 0.48) or TSH
(P: 0.83).
There was no overall statistically significant association
between serum TSH levels and breast cancer (Table 4).
In the analyses stratified for BMI, there was a weak,
non-significant association between high T3 levels and
breast cancer in the group with BMI over 25, the RR for
the fourth vs. the first quartile was 2.41 (0.99 to 5.84), as
compared to the corresponding RR in women with BMI
below 25, 1.31 (0.72 to 2.41) (other data not shown).
Adjusted RRs were very similar to crude RRs with
regard to both T3 and TSH. When women who devel-
≤ 160 24.1 28.8 28.9 36.5 29.7
>160 ≤ 165 32.6 33.2 30.9 30.7 32.0
>165 ≤ 170 26.7 24.9 25.0 22.0 24.6
>170 16.6 13.1 15.1 10.7 13.7
Education
<12 years 53.0 53.6 62.5 64.2 57.9
12 years 20.9 27.4 22.1 21.8 23.5
>12 years 21.7 14.9 11.2 10.7 14.5
Missing 4.5 4.1 4.2 3.2 4.0
Married 54.9 54.4 51.3 50.3 52.9
missing 0.8 1.8 7.2 14.5 5.8
Abbreviations: T3, triiodothyronine; HRT, hormone replacementtherapy; OC, oral contraceptives; BMI, body mass index.
Table 1: Distribution of potential risk factors for breast cancer according to serum T3 level (Continued)Tosovic et al. Breast Cancer Research 2010, 12:R33
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Table 2: Distribution of potential risk factors for breast cancer according to serum TSH level
Factor TSH quartile
1234 A l l
N = 647 N = 528 N = 793 N = 710 N = 2,678
Column percent
(TSH levels in italics)
TSH (mIU/l)
period I <1.50 1.60 to 2.00 2.10 to 3.00 ≥3.10
period II <0.90 1.00 to 1.30 1.40 to 2.00 ≥2.10
Age
<50 21.5 42.6 40.9 24.9 32.3
>50 78.5 57.4 59.1 75.1 67.7
Premenopausal 24.0 41.9 41.5 27.3 33.6
Peri/
postmenopausal
76.0 58.1 58.5 72.7 66.4
HRT in peri/
postmenopausal
17.3 20.8 17.2 13.0 16.6
missing 0.2 - - - 0.1
Nulliparity 13.9 13.1 18.0 18.2 16.1
missing 1.4 1.9 0.5 0.3 0.9
OC-use 3.7 8.7 8.7 4.4 6.3
missing 1.7 2.1 0.8 0.3 1.1
Menarche <12 
years
13.4 12.5 13.0 12.0 12.7
missing 2.3 3.6 1.0 0.6 1.7
Smoking
never 42.2 41.9 47.9 51.0 46.2
current 36.0 36.9 31.9 29.7 33.3
ex 20.2 19.3 19.7 18.9 19.5
missing 1.5 1.9 0.5 0.4 1.0
Alcohol 
consumption
nothing 17.0 12.3 14.2 16.5 15.1
less than 
every week
59.4 53.2 57.8 60.0 57.8
every week 21.5 30.7 26.5 23.0 25.2
missing 2.2 3.8 1.5 0.6 1.9
BMITosovic et al. Breast Cancer Research 2010, 12:R33
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oped breast cancer within three years after screening
were excluded from the analyses, all results were similar
for T3, but for TSH in premenopausal women, the risk in
the second quartile was even stronger (Tables 3 and 4).
The analyses of combinations of low and high T3/TSH
levels showed a statistically significant association for
crude RR in the highT3/highTSH groups, as compared to
the low/low category (1.62: 1.01 to 2.60). The association
was, however, not statistically significant in the adjusted
analysis (1.63: 0.99 to 2.69). The data were also stratified
for TSH, below and above median with regard to T3
quartiles. There was a statistically significant risk for
breast cancer in the highest T3 quartile (2.69: 1.19 to
6.08) in women with a TSH above the median. The corre-
sponding RR in women with low TSH levels was 1.62
(0.68 to 3.86). There was no statistically significant inter-
action between T3 and TSH in the whole cohort, in pre-
menopausal or peri/postmenopausal women.
When the analyses were repeated, excluding the
women born in 1935, all results were similar, crude RR =
5.56 (1.66 to 18.57) for postmenopausal women in the
highest T3 quartile (other data not shown).
Also, the analyses were repeated excluding women
treated with HRT and OC, and the results were similar,
crude RR = 6.50 (1.99 to 21.2) for postmenopausal
women in the highest T3 quartile (other data not shown).
Discussion
This is the first prospective study on T3 levels in relation
to breast cancer risk. It shows that T3 levels in postmeno-
pausal women are positively associated with the risk of
breast cancer in a dose-response manner.
It may be asked whether breast cancer cases in this
cohort are representative of the whole breast cancer pop-
ulation. This cohort mainly comprised middle-aged
women and 70% of the women invited to the health
examination attended. As we have no information about
exposure to the studied risk factors in women outside this
cohort, observed incidence rates may not be applicable to
all age groups or to the general population. However, as
there was a wide distribution of T3 and TSH levels, it was
possible to make internal comparisons between subjects
with low and high values, respectively. We consider that
our estimations of relative risks were not considerably
affected by selection bias.
Incomplete follow-up may affect the results. However,
the Swedish Cancer Registry and the Swedish Cause-of-
Death Registry have been validated and found to have a
completeness of about 99% [25].
Subjects with elevated T3 levels and a possible diagno-
sis of hyperthyroidism may already be within the health
care system and due to this the diagnosis of breast cancer
might be established earlier than for euthyroid subjects.
<20 10.0 11.6 9.1 7.3 9.3
≥20 <25 53.3 50.8 57.9 52.0 53.8
≥25 <30 26.9 27.3 23.8 28.9 26.6
≥30 9.7 10.4 9.2 11.8 10.3
Height
≤ 160 30.3 26.9 29.5 33.9 30.4
>160 ≤ 165 32.8 29.5 31.8 33.2 32.0
>165 ≤ 170 26.0 27.5 25.3 21.7 24.9
>170 11.0 16.1 13.4 11.1 12.7
Education
<12 years 58.6 54.4 55.1 61.0 57.4
12 years 23.3 24.6 26.4 22.0 24.1
>12 years 14.2 18.8 14.2 13.2 14.9
missing 3.9 2.3 4.3 3.8 3.7
Married 45.0 49.6 51.2 54.9 50.4
missing 19.6 25.0 7.6 4.2 13.0
Abbreviations: TSH, thyrotropin; HRT, hormone replacementtherapy; OC, oral contraceptives; BMI, body mass index.
Table 2: Distribution of potential risk factors for breast cancer according to serum TSH level (Continued)T
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Table 3: Breast cancer incidence in pre-, peri/postmenopausal and all women in relation to serum T3 levels
Group T3
(quartile)
Individuals
(n)
Breast cancer
cases
(n)
Person-years Incidence/100,000 All cases Cases >3 years following
Baseline examination
RR
(CI: 95%)
RR**
(CI: 95%)
RR
(CI: 95%)
RR**
(CI: 95%)
All 1 494 28 10,418 269 1.00 1.00 1.00 1.00
2 704 40 14,613 274 1.02 (0.63 to 1.66) 1.12 (0.69 to 1.84) 1.10 (0.66 to 1.83) 0.99 (0.60 to 1.66)
3 456 31 9,096 341 1.28 (0.77 to 2.13) 1.42 (0.83 to 2.43) 1.37 (0.78 to 2.42) 1.21 (0.70 to 2.10)
4 531 47 10,091 466 1.75 (1.10 to 2.80)* 1.87(1.12 to 3.14)* 1.98 (1.15 to 3.38)* 1.78 (1.10 to 2.90)*
P-trend 0.007 0.009 0.007 0.008
Premenopausal 1 298 25 6,376 392 1.00 1.00 1.00 1.00
2 311 21 6,621 317 0.81 (0.45 to 1.45) 1.00 (0.55 to 1.81) 1.00 (0.53 to 1.87) 0.80 (0.43 to 1.46)
3 131 7 2,816 249 0.63 (0.27 to 1.47) 0.71 (0.30 to 1.70) 0.79 (0.33 to 1.91) 0.69 (0.33 to 1.61)
4 123 9 2,610 345 0.88 (0.41 to 1.88) 0.92 (0.40 to 2.15) 1.07 (0.45 to 2.50) 0.96 (0.44 to 2.10)
P-trend 0.49 0.66 0.94 0.99
Peri/post-
menopausal
1 196 3 4,042 74 1.00 1.00 1.00 1.00
2 393 19 7,992 237 3.24 (0.96 to 10.9) 3.26 (0.96 to 11.1) 2.75 (0.80 to 9.48) 2.90 (0.85 to 9.91)
3 325 24 6,281 382 5.21 (1.57 to 17.4)* 5.53 (1.65 to 18.6)* 4.63 (1.35 to 15.8)* 4.39 (1.30 to 14.8)*
4 408 38 7,481 508 6.94 (2.14 to 22.5)* 6.87 (2.09 to 22.6)* 6.14 (1.86 to 20.3)* 6.49 (1.99 to 21.1)*
P-trend <0.001 <0.001 <0.001 <0.001
Abbreviations: T3, triiodothyronine; RR, relative risk; RR**, relative risk adjusted for age (continuous), menopausal status (in analysis of all women), use of HRT, nulliparity, use of oral contraception, 
age at menarche, smoking status, alcohol consumption, BMI, height, educational level and marital status, * P < 0.05.T
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Table 4: Breast cancer incidence in pre-, peri/postmenopausal and all women in relation to serum TSH levels
Group TSH
(quartile)
Individuals
(n)
Breast cancer
cases
(n)
Person-years Incidence/100,000 All cases Cases >3 years following
Baseline examination
RR
(CI: 95%)
RR**
(CI: 95%)
RR
(CI: 95%)
RR**
(CI: 95%)
All 1 647 40 11,764 340 1.00 1.00 1.00 1.00
2 528 42 9,517 441 1.05 (0.70 to 1.58) 1.07 (0.71 to 1.62) 1.28 (0.81 to 2.01) 1.26 (0.80 to 1.97)
3 793 55 15,829 347 0.93 (0.62 to 1.41) 0.94 (0.62 to 1.42) 1.20 (0.77 to 1.87) 1.19 (0.76 to 1.85)
4 710 36 14,521 248 0.87 (0.55 to 1.37) 0.80 (0.50 to 1.27) 0.95 (0.57 to 1.57) 1.03 (0.62 to 1.69)
P-trend 0.46 0.29 0.82 0.94
Premenopausal 1 155 10 3,170 315 1.00 1.00 1.00 1.00
2 221 18 4,669 386 1.48 (0.76 to 2.90) 1.38 (0.69 to 2.77) 1.91(0.90 to 4.08) 2.02 (0.97 to 4.23)
3 329 28 6,869 408 0.95 (0.48 to 1.87) 0.94 (0.47 to 1.87) 1.31(0.62 to 2.79) 1.30 (0.62 to 2.72)
4 194 7 4,213 166 0.81 (0.36 to 1.86) 0.62 (0.26 to 1.46) 0.88 (0.35 to 2.21) 1.11 (0.46 to 2.67)
P-trend 0.42 0.20 0.64 0.91
Peri/post-
menopausal
1 492 30 8,593 349 1.00 1.00 1.00 1.00
2 307 24 4,848 495 0.86 (0.51 to 1.45) 0.87 (0.51 to 1.47) 0.93 (0.52 to 1.67) 0.94 (0.53 to 1.67)
3 464 27 8,960 301 0.93 (0.56 to 1.56) 0.94 (0.56 to 1.58) 1.13 (0.65 to 1.98) 1.14 (0.66 to 1.99)
4 516 29 10,308 281 0.88 (0.51 to 1.53) 0.82 (0.47 to 1.43) 0.89 (0.48 to 1.65) 0.97 (0.53 to 1.78)
P-trend 0.73 0.57 0.94 0.87
Abbreviations: TSH, thyrotropin; RR, relative risk; RR**, relative risk adjusted for age (continuous), menopausal status (in analysis of all women), use of HRT, nulliparity, use of oral contraception, age 
at menarche, smoking status, alcohol consumption, BMI, height, educational level and marital status. * P < 0.05.Tosovic et al. Breast Cancer Research 2010, 12:R33
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However, general mammography screening was intro-
duced in Sweden already in 1986 and stands for the
majority of detection of breast cancer cases [26]. It is
unlikely that the thyroid status does affect participation
in mammography screening, hence a possible detection
bias in hyperthyroid breast cancer patients was probably
not important. It should also be noted that most women
with T3 levels in the fourth quartile in the present study
still had levels within the normal range, and these women
did probably not have any symptoms of thyroid disease.
T h e  m e t h o d  o f  a n a l y s i s  f o r  T 3  r e m a i n e d  t h e  s a m e
throughout the study. Not all women in the study popula-
tion had information on T3, but our analyses showed no
difference in risk of breast cancer in relation to T3 when
the group screened in 1990 was excluded. Hence, there
was probably no major selection bias due to the inclusion
of only some subjects with information on T3 in the later
period.
The method of analyses for TSH changed between 1983
and 1990 as did the reference values. This was taken into
account in our statistical analysis.
There is a well known circadian and seasonal variation
concerning T3 and TSH levels [27]. Tracking of individu-
als, that is, ranking of individuals over time is, however,
quite stable [28]. A true variation over time would most
likely have led to a un-differential misclassification of T3
and TSH, and, hence, attenuated observed risks.
The use of total T3 as a marker of T3 status involves an
important methodological aspect. Most T3 in the circula-
tion is bound to three transport proteins, thyroxin bind-
ing globulin (TBG), transthyretin and albumin. An
increased TBG concentration leads to higher levels of
total T3, and this is important to consider in studies of
breast cancer risk, as exogenous estrogens, that are risk
factors for breast cancer, that is, HRT and OC, led to
increased TBG binding capacity [29]. In order to exclude
the association between total T3 levels and breast cancer
risk as only an effect of differences in the use of HRT and
OC, we adjusted our analyses for HRT and OC. More-
over, the analyses in postmenopausal women were
repeated excluding women that had used HRT or OC.
Following that exclusion, the RR for T3, as compared to
the first quartile, was in the second quartile 3.11 (0.92 to
10.6), in the third 4.55 (1.35 to 15.3) and in the fourth
quartile 6.50 (1.99 to 21.2). Hence, both adjustment for
HRT/OC and exclusion of subjects using these medica-
tions resulted in similar risk estimates as were seen in the
main analysis. This finding, together with the notion that
there is no known association between endogenous
estrogen levels and TBG [29], makes it unlikely that the
results in the present study were caused by differences
with regard to TBG levels.
In the questionnaire used to collect data from the par-
ticipants, there was no information on co-morbidities or
medication which may affect the thyroid function, for
example, propanolol, salicylates and phenytoin. This is a
limitation in the study, but as there is no known associa-
tion between such factors and breast cancer risk, the
effect from uncontrolled confounding was probably
small. There was no information on thyroxin use specifi-
cally in the questionnaire, which is another limitation.
This was handled by excluding women who affirmed any
treatment for goiter, which probably limited the interfer-
ence with the results in the present study. However, the
current material did not allow any assessment of the risk
of breast cancer following thyroxin therapy.
The current study is the largest prospective study to
date on T3/TSH levels and breast cancer risk, but the
number of cases was limited. Confidence intervals were
wide and the statistical power relatively low. This led to
an imprecision in the estimates related to T3, and there is
a risk that the lack of association between TSH and breast
cancer was due to a type II error.
A large number of epidemiological studies have been
performed during the last 50 years on benign thyroid
conditions in relation to breast cancer [9-14,30-32], and
at least seven studies included more than 1,000 breast
cancer cases [9-14,30]. However, most previous studies
show no association between thyroid condition and
breast cancer. A methodological problem is that the great
majority of these studies were cross-sectional; hence it
may be difficult to establish a potential causal relation-
ship between thyroid disorders and breast cancer. A study
by Cristofanilli et al., including 1,136 breast cancer cases,
reported that women with previous hypothyroid condi-
tions had an increased risk of breast cancer [30]. Another
prospective study including a cohort of 2,775 women
found that previous hypothyroidism and the use of thy-
roid medications was associated with an odds ratio of 3.8
for breast cancer [16]. An indirect evidence of an associa-
tion between hypothyroidism and breast cancer is offered
by studies following women treated for thyroid cancer
(that is, by surgery or radio isotopes causing a hypothy-
roid state). For example, Brown et al. used the SEER reg-
istry and found an increased risk of breast cancer in
women with a previous diagnosis of thyroid cancer [33].
These three studies were prospective, but a methodologi-
cal problem is that the majority of these patients had
been treated with thyroxin. That is, the results may have
been confounded by exposure to exogenous thyroid hor-
mones. Moreover, as the above studies used information
on thyroid disorders usually obtained by interviews or
record-linkage with diagnosis registries thyroid hormone
levels were not directly measured. Thus, these studies do
not rule out the possibility that sub-clinical hyperthyroid
conditions, or even elevated T3 levels within the normal
range, may play a role in breast cancer pathogenesis.Tosovic et al. Breast Cancer Research 2010, 12:R33
http://breast-cancer-research.com/content/12/3/R33
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Some previous cross-sectional studies have found that
high T3 levels are positively associated with breast cancer
[1,5,7], among them the largest study to date including
226 cases (mean age 55 years, range 28 to 79) and 166
controls (mean age 46 years, range 17 to 65) [5]. Turken et
al. examined 150 cases and 100 controls, and the results
indicated that high T4 levels were associated with breast
cancer [4]. On the other hand, several reports have sug-
gested an association between low T3 [8,24,34] and/or
low T4 levels [8] and breast cancer risk. Indeed, the only
prospective study found a negative association between
T4 levels and breast cancer risk [16]. Finally some studies
did not show any associations at all with regard to T3/T4
and breast cancer [17,35,36], the two largest with 356 and
136 cases, respectively [35,7]. High TSH levels have been
associated with breast cancer risk in some studies [24,37],
but the only prospective analysis to date found a negative
association [16]. Yet, most have found no association
between TSH levels and breast cancer [3,5,7,8,35,36,38-
40]. One study found that TSH is low in cases among
postmenopausal women but high in cases among pre-
menopausal [1], indicating that menopause status may
modify the potential association between thyroid hor-
mones and risk of breast cancer. Autoimmune thyroid
diseases (defined as the presence of thyroid peroxidase
antibodies; TPOab) have been positively associated with
breast cancer risk in several cross-sectional studies
[4,17,40]. It is unclear whether the presence of TPOab in
serum from patients with breast cancer is related to an
increased risk following TPOab related conditions or if it
is a general autoimmune response to the malignancy [41].
Indeed, the only prospective study showed that the pre-
diagnostic presence of TPOab was not related to the sub-
s e q u e n t  r i s k  o f  b r e a s t  c a n c e r  [ 1 6 ] .  I n  o u r  p r o s p e c t i v e
study, breast cancer cases diagnosed within three years
after screening were excluded, hence the effect of (sub-
clinical) cancer disease on thyroid hormones or TSH, that
is, reverse causality, is unlikely.
The presence of thyroid hormone receptors in human
breast and breast cancer cell lines has been established
[42-45], and the proliferative effect of T3 has been con-
firmed by various experimental studies on breast cancer.
Our findings are in line with these data [1-3,46].
I t  h a s  be e n  s h o w n  t h a t  T 3  b i n d s  a n d  s t i m u l a t e s  t h e
e s t r o g e n  r e c e p t o r ,  a c t i n g  i n  s y n e r g y  w i t h  e s t r o g e n  o n
breast cancer cell lines, potentiating the estrogenic effect
and enhancing cell proliferation [47]. The role of estrogen
in carcinogenesis of the breast is well known and the pos-
sibility that this effect may be even stronger in conjunc-
t i o n  w i t h  h i g h  l e v e l s  o f  T 3  c o u l d  i n  p a r t  e x p l a i n  t h e
results in the present study.
Obesity is associated with increased breast cancer risk
in postmenopausal women [48]. Estrogen levels are
higher in obese compared to normal weight women. The
potentiating effect of T3 might further increase the risk
in this subgroup. Although our results did not reach sta-
tistical significance, they are in line with this hypothesis.
The significant positive association between T3 and
breast cancer is specifically strong in postmenopausal
women. Therefore, an imbalance between estrogen and
T3 with an increased T3/E2 ratio may be more important
than a pure synergistic effect between these two hor-
mones for the risk of developing breast cancer. It has
been suggested that this imbalance might enhance breast
cancer development [1]. This theory is in accordance
with our findings that higher T3 levels in postmenopausal
women are positively associated with the risk of breast
cancer in a dose-response manner. The present study
excluded women with a previous treatment for goiter and
there was no information on thyroxin use. An important
issue for future studies will be to evaluate the widespread,
long-term use of thyroxin treatment in TSH suppressive
doses for benign thyroid disease [49,50], and the manage-
ment of women with subclinical hyperthyroidism [51-
53]. Such studies will contribute with important evidence
whether or not to treat mild and/or sub-clinical thyroid
disorders.
Conclusions
In conclusion, the present prospective cohort study, the
first of its kind on prospectively measured T3 levels and
breast cancer risk, indicates that high T3 levels in post-
menopausal women are positively associated with the
risk of breast cancer in a dose-response manner.
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